Cara Therapeutics Inc. logo

CARA

Cara Therapeutics Inc. · NASDAQ

Website

Cara Therapeutics Inc. (CARA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for CARA in the last 30 days. The most recent was published Apr 21, 2025.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Latest news

25 items

CARA FAQ

8 questions
  • What does Cara Therapeutics Inc. do?
    Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis...
  • What is the latest news on CARA?
    Quantisnow has not tracked any new filings, ratings or press releases for CARA in the last 30 days. The most recent wire item was published on April 21, 2025.
  • Where does CARA stock trade?
    Cara Therapeutics Inc. (CARA) is listed on NASDAQ.
  • What sector and industry is CARA in?
    Cara Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Cara Therapeutics Inc. go public?
    Cara Therapeutics Inc. (CARA) completed its IPO in 2014.
  • What are analysts saying about CARA?
    Across the last 8 analyst actions on Cara Therapeutics Inc., there was 1 upgrade and 5 downgrades. The most recent action was from Stifel: Hold with a $1.00 price target on 2024-06-13.
  • What companies are similar to CARA?
    Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), ABT (Abbott Laboratories), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC). Compare CARA side-by-side with any of them on Quantisnow.
  • How can I track CARA on Quantisnow?
    Quantisnow aggregates Cara Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CARA to receive live email and push alerts on every new disclosure.